Arvinas says FDA approves VEPPANU for ESR1-mutated ER+/HER2- advanced breast cancer

Arvinas, Inc.
Pfizer Inc.

Arvinas, Inc.

ARVN

0.00

Pfizer Inc.

PFE

0.00
  • FDA cleared Arvinas-Pfizer drug VEPPANU (vepdegestrant) for adults with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer following at least one line of endocrine therapy.
  • Decision came ahead of June 5, 2026 PDUFA date.
  • Approval was based on Phase 3 VERITAC-2 data showing 43% lower risk of progression or death versus fulvestrant in ESR1-mutant patients.
  • Arvinas, Pfizer plan to select third-party partner to commercialize VEPPANU.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605011243PRIMZONEFULLFEED9711572) on May 01, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.